Literature DB >> 3618580

Prevention of perinatal transmission of hepatitis B virus: the sensitivity, specificity, and predictive value of the recommended screening questions to detect high-risk women in an obstetric population.

G M McQuillan, T R Townsend, C B Johannes, T Dillard, R A Molteni, P M Ness, J R Niebyl.   

Abstract

The Advisory Committee on Immunization Practices recommends that all pregnant women be questioned concerning risk factors for hepatitis B virus infection and that those giving positive responses be serotested. The sensitivity, specificity, and predictive value of those recommended questions among 692 parturient women were determined. A total of 59 currently or previously infected women (hepatitis B surface antigen (HBsAg), antibody to hepatitis B surface antigen (anti-HBs), or antibody to hepatitis B core antigen (anti-HBc) seropositive) were compared with the 633 seronegative women. Among nonwhite women, the sensitivity of a positive response to any one of the recommended questions was 60%. Specificity and positive predictive value were 71% and 19%, respectively. Among white women, the sensitivity, specificity, and positive predictive value were 56%, 75%, and 11%, respectively. To increase such unacceptably low sensitivity, the authors included two additional questions: single marital status and Medicaid/medical assistance payer status. Sensitivity increased to 96% among nonwhite women and 84% among white women. However, a positive response to at least one of the recommended questions or to additional questions was elicited from 78% of all women (92% nonwhite and 64% white). The authors conclude that to prevent perinatal transmission of hepatitis B, we must serotest all women in our obstetric population.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3618580     DOI: 10.1093/oxfordjournals.aje.a114680

Source DB:  PubMed          Journal:  Am J Epidemiol        ISSN: 0002-9262            Impact factor:   4.897


  8 in total

Review 1.  Management of patients with hepatitis B who require immunosuppressive therapy.

Authors:  Jessica P Hwang; Anna S-F Lok
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-11-19       Impact factor: 46.802

2.  Canadian Immunization Guide.

Authors: 
Journal:  CMAJ       Date:  1989-08-01       Impact factor: 8.262

3.  Ante-natal screening for hepatitis B surface antigen: an appraisal of its value in a low prevalence area.

Authors:  M J Dwyer; P G McIntyre
Journal:  Epidemiol Infect       Date:  1996-08       Impact factor: 2.451

4.  Preventing hepatitis B reactivation in immunosuppressed patients: is it time to revisit the guidelines?

Authors:  Jinoos Yazdany; Leonard Calabrese
Journal:  Arthritis Care Res (Hoboken)       Date:  2010-05       Impact factor: 4.794

5.  Success of a program of routine prenatal screening for hepatitis B surface antigen: the first 2 years.

Authors:  N B Okun; R P Larke; J R Waters; M R Joffres
Journal:  CMAJ       Date:  1990-12-15       Impact factor: 8.262

Review 6.  Hepatitis B in pregnancy.

Authors:  J A Arevalo
Journal:  West J Med       Date:  1989-06

7.  Reactivation of hepatitis B during immunosuppressive therapy: potentially fatal yet preventable.

Authors:  Anna S F Lok; John W Ward; Robert P Perrillo; Brian J McMahon; T Jake Liang
Journal:  Ann Intern Med       Date:  2012-05-15       Impact factor: 25.391

8.  Prevalence of hepatitis B and C and sensibility of a selective screening questionnaire in patients receiving chemotherapy for solid tumors.

Authors:  Mathilde Brasseur; Alexandra Heurgué-Berlot; Coralie Barbe; Cloé Brami; Jean-Baptiste Rey; Juliette Vella-Boucaud; Fadia Dabouz; Gaëtan Deslée; Florent Grange; Julien Volet; Olivier Bouché
Journal:  BMC Cancer       Date:  2015-12-23       Impact factor: 4.430

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.